Dr. Reddy's inks strategic licensing deal for cancer immunotherapy

Dr. Reddy's Laboratories SA, a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited, has signed an exclusive licensing agreement with Immutep SAS, a subsidiary of Immutep Limited. This collaboration grants Dr. Reddy's the rights to develop and commercialize Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China.

Under the terms of the agreement, Immutep will receive an upfront payment of $20 million. Additionally, Immutep is eligible for potential regulatory, development, and commercial milestone payments totaling up to $349.5 million, along with double-digit royalties on commercial sales.

Eftilagimod Alfa, a first-in-class novel immunotherapy, is currently in a registrational Phase III trial for first-line therapy of advanced or metastatic non-small cell lung cancer, with broad potential across various major cancers. This deal enhances Dr. Reddy's efforts to deliver innovative cancer treatments and leverage its market access.